Literature DB >> 9236142

Genistein, a tyrosine kinase inhibitor, blocks the "second window of protection" 48 h after ischemic preconditioning in the rabbit.

J i Imagawa1, G F Baxter, D M Yellon.   

Abstract

We have previously reported a delayed or "second window of protection" against infarction 24-72 h after ischemic preconditioning in the rabbit. This phenomenon has also been associated with the protein kinase C signalling pathway. In the present study, we expanded our investigation to ascertain whether protein tyrosine kinase was in any way associated with this phenomenon in the rabbit heart. We found that 48 h after ischemic preconditioning with 4x5 min coronary occlusions the percentage of myocardium infarcting within the risk zone following a 30-min coronary occlusion and 120-min reperfusion (I/R) was reduced from 39. 6+/-3.3% to 18.0+/-3.7% (P<0.01). However, an i.v. bolus administration of genistein (5 mg/kg), a tyrosine kinase inhibitor, 5 min before ischemic preconditioning stimulus, abolished this protection (I/R=39.0+/-3.4%). Genistein per se had no significant effect on infarction 48 h later. Risk zone volume after coronary ligation was not significantly different between intervention groups. There were no differences in hemodynamic parameters between groups throughout the experimental period. We conclude that the second window of protection, 48 h after preconditioning, is mediated by tyrosine kinase activation in the rabbit heart.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236142     DOI: 10.1006/jmcc.1997.0428

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

Review 1.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

2.  Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury.

Authors:  B Deodato; D Altavilla; G Squadrito; G M Campo; M Arlotta; L Minutoli; A Saitta; D Cucinotta; G Calapai; A P Caputi; M Miano; F Squadrito
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Pharmacological evidence that inducible nitric oxide synthase is a mediator of delayed preconditioning.

Authors:  J Imagawa; D M Yellon; G F Baxter
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Reactive oxygen species in early and delayed cardiac adaptation.

Authors:  E Roth; M T Jaberansari
Journal:  Exp Clin Cardiol       Date:  2001

5.  An essential role of the JAK-STAT pathway in ischemic preconditioning.

Authors:  Y T Xuan; Y Guo; H Han; Y Zhu; R Bolli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

6.  Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.

Authors:  K Shinmura; X L Tang; Y Wang; Y T Xuan; S Q Liu; H Takano; A Bhatnagar; R Bolli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 7.  The nitric oxide hypothesis of late preconditioning.

Authors:  R Bolli; B Dawn; X L Tang; Y Qiu; P Ping; Y T Xuan; W K Jones; H Takano; Y Guo; J Zhang
Journal:  Basic Res Cardiol       Date:  1998-10       Impact factor: 17.165

8.  Hypercholesterolemia blunts NO donor-induced late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Adam B Stein; Gregg Shirk; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2004-09-16       Impact factor: 17.165

9.  Demonstration of an early and a late phase of ischemic preconditioning in mice.

Authors:  Y Guo; W J Wu; Y Qiu; X L Tang; Z Yang; R Bolli
Journal:  Am J Physiol       Date:  1998-10

10.  Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.

Authors:  J Gierten; E Ficker; R Bloehs; K Schlömer; S Kathöfer; E Scholz; E Zitron; C Kiesecker; A Bauer; R Becker; H A Katus; C A Karle; D Thomas
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.